SCHEMBL13633452

SCHEMBL13633452

Nc1cn2ccc(Br)cc2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 1/20 0.56
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
KDM4E B2RXH2 3/20 0.41
SUV39H2 Q9H5I1 2/20 0.38
AHR P35869 2/20 0.38
BACE1 P56817 2/20 0.37
DYRK1A Q13627 1/20 0.37
METTL3 Q86U44 2/20 0.36
TLR9 Q9NR96 2/20 0.36
TLR7 Q9NYK1 2/20 0.36
SMN1; SMN2 Q16637 3/20 0.34
POLB P06746 1/20 0.34
TP53 P04637 1/20 0.34
ALOX12 P18054 1/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31528556 0.80 NPC1 (0.44) PIK3CGNPC1RAB9AKDM4ESUV39H2
SCHEMBL31528509 0.77 METTL3 (0.44) NPC1RAB9AKDM4EAHRMETTL3
SCHEMBL1426603 0.77 HDAC1 (0.50) NPC1RAB9AKDM4ESUV39H2AHR
SCHEMBL15240535 0.77 METTL3 (0.44) NPC1RAB9AKDM4ESUV39H2AHR
SCHEMBL30306988 0.74 METTL3 (0.45) NPC1RAB9AKDM4EAHRMETTL3
SCHEMBL31706121 0.74 METTL3 (0.46) NPC1RAB9AKDM4EDYRK1AMETTL3
SCHEMBL20600553 0.73 METTL3 (0.44) NPC1RAB9AKDM4EAHRMETTL3
SCHEMBL22129495 0.73 TLR9 (0.52) PIK3CGNPC1RAB9AKDM4ESUV39H2
SCHEMBL20540263 0.73 KDM4E (0.39) NPC1RAB9AKDM4ESUV39H2AHR
SCHEMBL1426320 0.73 KDM4E (0.39) NPC1RAB9AKDM4ESUV39H2AHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11993595-B2 Compounds MISSION THERAPEUTICS LIMITED (GB) 2024-05-28 US disclosed
CN-111592534-B New compounds 特殊治疗有限公司 2023-06-30 CN disclosed
US-20230052191-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2023-02-16 US disclosed
US-11472798-B2 Compounds MISSION THERAPEUTICS LTD (GB) 2022-10-18 US disclosed
US-20210371433-A1 Novel Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-12-02 US disclosed
EP-3828179-A1 CYANOPYRROLIDINES AS DUB MODULATORS Mission Therapeutics Limited (GB) 2021-06-02 EP disclosed
US-20200369658-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2020-11-26 US disclosed
US-10774078-B2 Compounds MISSION THERAPEUTICS LTD (GB) 2020-09-15 US disclosed
CN-111592534-A Novel compounds 特殊治疗有限公司 2020-08-28 CN disclosed
EP-3197883-B1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2020-03-18 EP disclosed
EP-3197883-A1 NOVEL COMPOUNDS Mission Therapeutics Limited (GB) 2017-08-02 EP disclosed
WO-2016046530-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2016-03-31 WO disclosed
WO-2016046530-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2016-03-31 WO disclosed
US-20090275577-A1 IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS PFIZER INC 2009-11-05 US disclosed
US-20090275577-A1 IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS PFIZER INC 2009-11-05 US disclosed
EP-1737459-B1 IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2009-08-05 EP disclosed
US-7563788-B2 Substituted Imidazo[1,2-a]pyridines as Antibacterial Agents PFIZER INC. (US) 2009-07-21 US disclosed
US-7563788-B2 Substituted Imidazo[1,2-a]pyridines as Antibacterial Agents PFIZER INC. (US) 2009-07-21 US disclosed
US-20070191394-A1 Antibacterial agents WARNER-LAMBERT COMPANY LLC 2007-08-16 US disclosed
US-20070191394-A1 Antibacterial agents WARNER-LAMBERT COMPANY LLC 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210371433-A1 Novel Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors PRMT5, PRMT1, PRMT8 PIK3CG 638/4885NPC1 2590/4885RAB9A 3003/4885
US-10774078-B2 Compounds UCHL1, UCHL3, UCHL5 PIK3CG 3030/4885NPC1 2436/4885RAB9A 519/4885
US-11472798-B2 Compounds UCHL1, UCHL3, UCHL5 PIK3CG 3030/4885NPC1 2436/4885RAB9A 519/4885
US-11993595-B2 Compounds UCHL1, UCHL3, UCHL5 PIK3CG 3030/4885NPC1 2436/4885RAB9A 519/4885
US-20070191394-A1 Antibacterial agents MRPL21, RPN2, FBL PIK3CG 1818/4885NPC1 575/4885RAB9A 707/4885
US-20200369658-A1 NOVEL COMPOUNDS UCHL1, UCHL3, UCHL5 PIK3CG 3076/4885NPC1 2546/4885RAB9A 480/4885
US-20090275577-A1 IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS DPYD, TYMP, ITPA PIK3CG 943/4885NPC1 1996/4885RAB9A 1510/4885
US-20230052191-A1 NOVEL COMPOUNDS UCHL1, UCHL3, UCHL5 PIK3CG 3076/4885NPC1 2546/4885RAB9A 480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.